Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Berry

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    16 result(s) found for: Berry. Displaying page 1 of 1.
    EudraCT Number: 2017-000514-35 Sponsor Protocol Number: Protect-U Start Date*: 2018-04-04
    Sponsor Name:Ruprecht-Karls-University Heidelberg, Medical Faculty Mannheim
    Full Title: Prospective Randomised Open-label Trial to Evaluate risk faCTor management in patients with Unruptured intracranial aneurysms (PROTECT-U)
    Medical condition: Saccular cerebral aneurysm
    Disease: Version SOC Term Classification Code Term Level
    20.1 10029205 - Nervous system disorders 10022758 Intracranial aneurysm PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) FI (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-003670-18 Sponsor Protocol Number: E-010-08-08 Start Date*: 2008-12-03
    Sponsor Name:Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts
    Full Title: Vasovist in MRI follow-up of embolized intracranial aneurysms at 3 Tesla – A prospective, multicenter, multinational, open-label, investigator initiated study
    Medical condition: Patients with intracranial aneurysm after coil embolization with suspicion of residual blood flow
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002337 Aneurysm intracranial LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001218-24 Sponsor Protocol Number: TDL-CS-001 Start Date*: 2014-06-05
    Sponsor Name:Trichocare Diagnostics Ltd
    Full Title: An open label, intra-subject, controlled multi-centre study to assess the concordance (specificity and sensitivity) between Colourstart® Test 73 mcg Cutaneous Patch and Finn Chamber in the detectio...
    Medical condition: Para-Phenylenediamine allergy
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004848 10065649 PPD skin test positive LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-002008-15 Sponsor Protocol Number: NL65095.041.18 Start Date*: 2018-06-08
    Sponsor Name:University Medical Center Utrecht
    Full Title: Optimal cerebral perfusion after an extracranial-intracranial bypass: should we increase blood pressure or cardiac output?
    Medical condition: Patients with an indication for an extracranial-intracanial bypass (e.g. Moya Moya Disease, occluded carotid artery, giant aneurysm)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10029999 Occlusion carotid LLT
    20.1 100000004852 10002333 Aneurysm cerebral LLT
    20.1 100000004852 10002337 Aneurysm intracranial LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-023536-16 Sponsor Protocol Number: ITN043AD Start Date*: 2011-02-25
    Sponsor Name:University of California, San Francisco, Immune Tolerance Network
    Full Title: A Randomised, Double-blind, Single-centre, Placebo controlled Study of Sublingual Immunotherapy and Subcutaneous Immunotherapy in Adults with Seasonal Allergic Rhinitis (ITN043AD)
    Medical condition: Grass-pollen induced rhinoconjunctivitis (hay fever).
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003819-71 Sponsor Protocol Number: DX-88/14 Start Date*: 2006-11-23
    Sponsor Name:Dyax Corp
    Full Title: EDEMA3: Evaluation of DX-88’s Effects in Mitigating Angioedema A double-blind, placebo-controlled study followed by a repeat dosing phase to assess the efficacy and safety of DX-88 (recombinant pl...
    Medical condition: Hereditary Angioedema
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003763-35 Sponsor Protocol Number: 2016_76 Start Date*: 2018-05-17
    Sponsor Name:centre hospitalier universitaire de Lille
    Full Title: Conservative Iron Chelation by Deferiprone as a disease-modifying Strategy for Amyotrophic Lateral Sclerosis using a Multicentre Parallel group, placebo controlled, Randomized clinical trial
    Medical condition: De novo Amyotrophic Lateral Sclerosis patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-010520-25 Sponsor Protocol Number: AMR-01-01-0016 Start Date*: 2009-12-08
    Sponsor Name:Amarin Pharma Inc.
    Full Title: A Phase 3, Multi-Center, Placebo-Controlled, Randomized, Double-Blind, 12-Week Study With an Open-Label Extension to Evaluate the Efficacy and Safety of AMR101 in Patients With Fasting Triglycer...
    Medical condition: Hypertriglyceridemia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10014486 Elevated triglycerides HLT
    9.1 10020870 Hypertriglyceridemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) DK (Prematurely Ended) FI (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002952-17 Sponsor Protocol Number: CVL-751-PD-004 Start Date*: 2021-03-30
    Sponsor Name:Cerevel Therapeutics, LLC
    Full Title: 58-Week Open-label Trial of Tavapadon in Parkinson’s Disease (TEMPO-4 Trial)
    Medical condition: Patients (40 to 80 years age) who have diagnosis of Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) FR (Trial now transitioned) CZ (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) BG (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-005486-21 Sponsor Protocol Number: GA1102 Start Date*: 2012-01-26
    Sponsor Name:Reckitt Benckiser Healthcare (UK) Ltd.
    Full Title: A multicentre, randomised, double-blind, two arm, parallel group, placebo controlled, pilot study to assess the effect of Gaviscon Advance as add-on therapy in GORD patients with inadequate respons...
    Medical condition: Gastro Oesophageal Reflux Disease (GORD)
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004856 10066874 Gastroesophageal reflux disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002950-22 Sponsor Protocol Number: CVL-751-PD-002 Start Date*: 2020-05-19
    Sponsor Name:Cerevel Therapeutics, LLC
    Full Title: A Phase 3, Double-Blind, Randomized, Placebo Controlled, Parallel Group, Flexible-Dose, 27 Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon in Early Parkinson’s Disease (T...
    Medical condition: Patients (40 to 80 years age) who have diagnosis of Parkinson's Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2019-002951-40 Sponsor Protocol Number: CVL-751-PD-003 Start Date*: 2020-07-29
    Sponsor Name:Cerevel Therapeutics, LLC
    Full Title: A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Flexible-Dose, 27-Week Trial to Evaluate the Efficacy, Safety, and Tolerability of Tavapadon as Adjunctive Therapy for Parki...
    Medical condition: Patients (40 to 80 years age) who have diagnosis of Parkinson's Disease with Motor Fluctuations
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10061536 Parkinson's disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) ES (Ongoing) FR (Completed) HU (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-002949-38 Sponsor Protocol Number: CVL-751-PD-001 Start Date*: 2020-02-06
    Sponsor Name:Cerevel Therapeutics, LLC
    Full Title: A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED, PARALLEL GROUP, 27 WEEK TRIAL TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON IN EARLY PARKINSON’S DISEAS...
    Medical condition: Patients (18 to 60 years age) who have diagnosis of Parkinson's Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) CZ (Completed) DE (Completed) FR (Completed) PL (Completed) ES (Ongoing) BG (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000441-20 Sponsor Protocol Number: TR02-108 Start Date*: 2011-06-29
    Sponsor Name:Insmed Incorporated
    Full Title: Randomized, open-label, active-controlled, multicenter study to assess the efficacy, safety and tolerability of Arikace™ in Cystic Fibrosis patients with chronic infection due to Pseudomonas aerug...
    Medical condition: Pseudomonas aeruginosa pulmonary infection / colonisation in patients with cystic fibrosis
    Disease: Version SOC Term Classification Code Term Level
    14.0 10010331 - Congenital, familial and genetic disorders 10011763 Cystic fibrosis lung PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) BE (Completed) IE (Completed) DE (Completed) AT (Completed) GR (Completed) NL (Completed) DK (Completed) ES (Completed) IT (Completed) BG (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2017-000497-11 Sponsor Protocol Number: ALK3831-A307 Start Date*: 2017-07-13
    Sponsor Name:Alkermes Inc
    Full Title: A Study to Evaluate the Effect of ALKS 3831 Compared to Olanzapine on Body Weight in Young Adults with Schizophrenia, Schizophreniform, or Bipolar I Disorder Who are Early in Their Illness
    Medical condition: Schizophrenia, schizophreniform disorder or bipolar I disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    21.1 10037175 - Psychiatric disorders 10039647 Schizophreniform disorder PT
    20.0 10037175 - Psychiatric disorders 10004939 Bipolar I disorder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) ES (Ongoing) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-000918-36 Sponsor Protocol Number: ALK3831-A308 Start Date*: 2017-07-21
    Sponsor Name:Alkermes Inc
    Full Title: A Phase 3 Study to Assess the Long Term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 in Subjects with Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder
    Medical condition: Schizophrenia, schizophreniform disorder or bipolar I disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    21.1 10037175 - Psychiatric disorders 10039647 Schizophreniform disorder PT
    20.0 10037175 - Psychiatric disorders 10004939 Bipolar I disorder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed) AT (Completed) ES (Completed) IE (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 30 12:41:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA